What Does GH Research PLC (GHRS)’s Clinical Progress Updates Say?

GH Research PLC (NASDAQ:GHRS) is among the best psychedelic stocks to buy in 2026. The company is advancing efforts to develop psychedelic medicines targeting conditions like depression, bipolar II disorder, and other psychiatric and neurological disorders. Its flagship drug candidate GH001 is aimed at patients with treatment-resistant depression as well as those with bipolar II disorder and postpartum depression. What Does GH Research PLC (GHRS)’s Clinical Progress Updates Say? On March 10, Guggenheim ...